A Phase 1 Single Dose PK Study in Adolescent Subjects With Fragile X Syndrome or Angelman Syndrome

Trial Profile

A Phase 1 Single Dose PK Study in Adolescent Subjects With Fragile X Syndrome or Angelman Syndrome

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Gaboxadol - Ovid Therapeuticsgaboxadol (Primary)
  • Indications Angelman syndrome; Fragile X syndrome
  • Focus Pharmacokinetics
  • Sponsors Ovid Therapeutics
  • Most Recent Events

    • 29 Nov 2017 Status changed from active, no longer recruiting to completed.
    • 28 Nov 2017 Results published in the Media Release
    • 28 Nov 2017 According to an Ovid Therapeutics media release, after successful completion of this trial, the company is planning to amend a Phase 2 trial (see profile 255964)and include adolescent patients aged 13 years and older in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top